Navigation Links
Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
Date:3/5/2008

Preclinical profile and potential for lower cardiac toxicity drives

investigator interest

SEATTLE, March 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that its investigational drug pixantrone will be studied in a multicenter phase I/II trial initiated by the Fondation Charcot Stichting, in Brussels, Belgium, which sponsors a consortium of centers involved in studying new therapies for the treatment for multiple sclerosis. This study will enroll patients with aggressive relapsing remitting (RR) or secondary progressive (SP) multiple sclerosis (MS). Mitoxantrone, a related compound which is less active in preclinical studies, has been approved by the U.S. Food and Drug Administration (FDA) for the reduction of neurological disability and/or frequency of clinical response in patients with SP MS. A phase III trial with pixantrone in relapsed aggressive non-Hodgkin's lymphoma (NHL) is near completion.

"Despite the availability of newer biologic agents, drugs such as mitoxantrone remain an important therapy in relapsing MS. Long term cardiotoxicity remains a major drawback to treating multiple sclerosis with mitoxantrone and imposes a limitation both for selection of patients and for the duration of the treatment," said R.E. Gonsette, M.D., Chairman Fondation Charcot Stichting and principal investigator of the study. "In addition to the potential for lower cardiac toxicity, preclinical studies suggest that pixantrone may provide more effective immune regulation than mitoxantrone, the only currently approved cytotoxic agent for treating MS."

The investigator-sponsored trial (IST) will enroll 20 patients in Belgium, France and Germany.

About the Study

Twenty patients with aggressive RR MS or SP MS who failed to respond to approved immunomodulatory agents (interferons, glatiramer acetate) will be included. The objectives of the study are to determine the
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
3. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
6. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
10. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
11. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... supplier of injectable drug delivery systems, today announced ... and facilities in response to increasing demand from ... services. During the fourth quarter of fiscal year ... capital expenditures and R&D above normal quarterly investments. ...
(Date:7/30/2014)... N.Y. , July 30, 2014 /PRNewswire-iReach/ -- ... -based medical device company, has announced today ... the velox CD™ Vascular Closure Device. Velox CD™ ... immediate hemostasis following percutaneous femoral procedures. The single ... broadly ranging in size from 5F to 8F.  ...
(Date:7/30/2014)... -- InnoPharma, Inc. today announced the first generic launch of ... injection), in Canada.  Olanzapine is indicated for the rapid ... schizophrenia or bipolar I mania. As the ... into an agreement with Sandoz Canada Inc., pursuant to ... market and distribute Olanzapine Injection in Canada ...
Breaking Medicine Technology:Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 4Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 5Transluminal Technologies receives CE Mark approval for velox CD(TM) vascular closure device 2InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2
... SIRO Clinpharm a leading Contract Research Organization (CRO) based out ... Nimita Limaye, PhD, SIRO Vice President and Global Head, Strategic Data ... the Society for Clinical Data Management (SCDM).   "I ... I hope that I will live up to the ...
... At this year,s Annual Meeting of the American ... (NYSE: PHG, AEX: PHI) is demonstrating how the ... simplify the clinician and patient experience. ... http://www.newscom.com/cgi-bin/prnh/20091127/NY17547LOGO ) Specially designed ...
Cached Medicine Technology:SIRO Clinpharm's Nimita Limaye Elected as Chairperson of Society for Clinical Data Management (SCDM) 2Philips Showcases Integrated Radiation Oncology Suite to Simplify Treatment Planning 2Philips Showcases Integrated Radiation Oncology Suite to Simplify Treatment Planning 3Philips Showcases Integrated Radiation Oncology Suite to Simplify Treatment Planning 4
(Date:7/30/2014)... July 31, 2014 “United States Orthopedic Braces ... on the United States Orthopedic Braces and Supports market. The ... (in units) and average price data (in US dollars), within ... , Ankle Braces and Supports , ... and Supports. , Orthotics is a specialty within ...
(Date:7/30/2014)... 30, 2014 Daily Gossip mentions that the ... an effective way to stop anxiety and eliminate all associated ... helped no less than 150,000 people in getting their lives ... a complex anxiety treatment system that will teach sufferers different ... method is very simple to access, as it is available ...
(Date:7/30/2014)... 30, 2014 Ticket Down is ... Munich vs. Chivas Guadalajara friendly exhibition match at the ... Cup, the one team that was left standing as the ... it through the world’s largest football competition and even embarrassed ... way to the cup. Germany was led by seven players ...
(Date:7/30/2014)... education in sub-Saharan Africa is being revitalized and ... increasing enrollment, broadening curricula, upgrading Internet access and ... , In the first substantial publication by participants ... (MEPI), more than 225 authors detailed progress being ... in a supplement being published today by the ...
(Date:7/30/2014)... Reinberg HealthDay Reporter WEDNESDAY, ... United States, at least 2,000 Americans die from extreme heat ... Heat waves, heat stroke or sun stroke caused nearly one-third ... 2010, according to the U.S. Centers for Disease Control and ... of body heat -- accounted for 63 percent of those ...
Breaking Medicine News(10 mins):Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 2Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 3Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 4Health News:Panic Away Review Reveals How to Stop Anxiety 2Health News:Bayern Munich vs. Chivas Guadalajara Tickets Red Bull Arena: Ticket Down Slashes Ticket Prices for Chivas Guadalajara vs. Bayern Munich in Harrison, NJ 2Health News:Bayern Munich vs. Chivas Guadalajara Tickets Red Bull Arena: Ticket Down Slashes Ticket Prices for Chivas Guadalajara vs. Bayern Munich in Harrison, NJ 3Health News:Journal supplement details progress in African medical education 2Health News:Journal supplement details progress in African medical education 3Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 2Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 3
... ... improved risk management and visibility at the management and board level , ... MetricStream, Inc., the market ... entered into an agreement with AEI, an emerging markets energy infrastructure company, to provide ...
... pressure monitoring (HBPM) program supported by the American Heart ... for patients with uncontrolled hypertension, according to a study. ... 18 to 85 years, and with Internet access were ... HBPM group. All patients had their blood pressure measured ...
... in or drive them away , FRIDAY, May 21 (HealthDay ... taste, two new studies reveal that harmonic arrangements and rhythm ... or drive them away. , The first study, from the ... of Current Biology , found that the musical chords ...
... ... in 2010; Allsup outlines 10 reasons to get SSDI representation, , ... Belleville, IL (Vocus) May 21, 2010 ... mark five times already by April. As millions of people inundate the agency, it’s ...
... , ... Water Enabled Technologies, LLC, Salt Lake City, Utah and Clemson University, Clemson, South ... a new process for desalination and with Clemson University will develop existing and ... water at a fraction of the energy currently required by RO or Evaboration ...
... ... against wrinkles -- up its sleeve. Make sure you tune in as we team up ... ... The Balancing Act just might have a secret weapon – against wrinkles -- up its sleeve. ...
Cached Medicine News:Health News:MetricStream Enters into Agreement to Provide Enterprise Risk Management Software Solution to AEI 2Health News:The Science Behind Musical Taste 2Health News:Choosing Representation Can Help Disability Applicants Avoid Long Lines at Social Security Offices 2Health News:Choosing Representation Can Help Disability Applicants Avoid Long Lines at Social Security Offices 3Health News:Choosing Representation Can Help Disability Applicants Avoid Long Lines at Social Security Offices 4Health News:Choosing Representation Can Help Disability Applicants Avoid Long Lines at Social Security Offices 5Health News:Water Enabled Technologies of Utah Signs MOU with Clemson University, South Carolina, for Water Desalination 2Health News:O2 Media's Hit Morning TV Show ‘The Balancing Act' Welcomes Absolute Miracle Cream to the Program 2
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
... The "three-in-one Microkeratome for traditional Lasik, Epi-Lasik ... a world of rapidly changing technologies and ... II is and remains a proven value, ... their needs and allows them to stay ...
Medicine Products: